Paediatric Respiratory Reviews
Volume 8, Issue 1 , Pages 62-66 , March 2007

Toxicological aspects and applications of nanoparticles in paediatric respiratory disease

References 

  1. Chang CY. The highlights in the nano world. Proc IEEE. 2003;91:1756–1764
  2. Dobson J. Magnetic nanoparticle-based targeting for drug and gene delivery. NanoMedicine. 2006;1:31–37
  3. Dobson J. Magnetic nanoparticles for drug delivery. Drug Devel Res. 2006;67:55–60
  4. Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater. 2005;4:435–446
  5. Smith AM, Dave S, Nie SM, True L, Gao XH. Multicolor quantum dots for molecular diagnostics of cancer. Expert Rev Mol Diagnostics. 2006;6:231–244
  6. Borm PJ. Particle toxicology: from coal mining to nanotechnology. Inhal Toxicol. 2002;14:311–324
  7. Murr LE, Esquivel EV, Bang JJ. Characterization of nanostructure phenomena in airborne particulate aggregates and their potential for respiratory health effects. J Mater Sci Mater Med. 2004;15:237–247
  8. Xiong C, Friedlander SK. Morphological properties of atmospheric aerosol aggregates. Proc Natl Acad Sci USA. 2001;98:11851–11856
  9. Chen Y, Chen J, Dong J, Jin Y. Comparing study of the effect of nanosized silicon dioxide and microsized silicon dioxide on fibrogenesis in rats. Toxicol Ind Health. 2004;20:21–27
  10. Warheit DB, Webb TR, Sayes CM, Colvin VL, Reed KL. Pulmonary instillation studies with nanoscale TiO2 rods and dots in rats: toxicity is not dependent on particle size and surface area. Toxicol Sci. 2006;91:227–236
  11. Muller J, Huaux F, Moreau N, Misson P, et al. Respiratory toxicity of multi-wall carbon nanotubes. Toxicol Appl Pharmacol. 2005;15:221–231
  12. Shvedova AA, Kisin ER, Mercer R, et al. Unusual inflammatory and fibrogenic pulmonary responses to single-walled carbon nanotubes in mice. Am J Physiol Lung Cell Mol Physiol. 2005;289:L698–L708
  13. Fiorito S, Serafino A, Andreola F, Togna A, Togna G. Toxicity and biocompatibility of carbon nanoparticles. J Nanosci Nanotechnol. 2006;6:591–599
  14. Sjøgren CE, Briley-Saebø K, Hanson M, Johansson C. Magnetic characterization of iron oxides for magnetic resonance imaging. Magn Reson Med. 1994;31:268–272
  15. Pankhurst QA, Connoly J, Jones SK, Dobson J. Applications of magnetic nanoparticles in biomedicine. J Phys D. 2003;36:R167–R181
  16. Muldoon LL, Sandor M, Pinkston KE, Neuwelt EA. Imaging, distribution, and toxicity of superparamagnetic iron oxide magnetic resonance nanoparticles in the rat brain and intracerebral tumor. Neurosurgery. 2005;57:785–796
  17. Haage P, Karaagac S, Spuntrup E, Truong HT, Schmidt T, Gunther RW. Feasibility of pulmonary ventilation visualization with aerosolized magnetic resonance contrast media. Invest Radiol. 2005;40:85–88
  18. Voura EB, Jaiswal JK, Mattoussi H, Simon SM. Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy. Nat Med. 2004;10:993–998
  19. Agrawal A, Tripp RA, Anderson LJ, Nie S. Real-time detection of virus particles and viral protein expression with two-color nanoparticle probes. J Virol. 2005;79:8625–8628
  20. Johnson CM, Pandey R, Sharma S, et al. Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2005;49:4335–4338
  21. Sharma A, Sharma S, Khuller GK. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother. 2004;54:761–766
  22. Zahoor A, Sharma S, Khuller GK. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents. 2005;26:298–303
  23. John AE, Lukacs NW, Berlin AA, et al. Discovery of a potent nanoparticle P-selectin antagonist with anti-inflammatory effects in allergic airway disease. FASEB J. 2003;17:2296–2298
  24. In:  Hodson ME,  Geddes DM editor. Cystic fibrosis. London: Chapman & Hall Medical; 1995;
  25. Schildow DV, Friel SB. Cystic fibrosis. In:  Albert RK,  Spiro SG,  Jett JR editor. Clinical Respiratory Medicine. St. Louis: Mosby; 2004;p. 19–29
  26. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994;331:637–642
  27. Wagener JS, Rock MJ, McCubbin MM, Hamilton SD, Johnson CA, Ahrens RC. Aerosol delivery and safety of recombinant human deoxyribonuclease in young children with cystic fibrosis: a bronchoscopic study. Pulmozyme Pediatric Broncoscopy Study Group. J Pediat. 1998;133:486–491
  28. Bueler H. Adeno associated viral vectors for gene transfer and gene therapy. Biol Chem. 1999;380:613–622
  29. Wickham TJ. Targeting adenovirus. Gene Ther. 2000;7:110–114
  30. Zaiss AK, Muruve DA. Immune responses to adeno-associated virus vectors. Curr Gene Ther. 2005;5:323–331
  31. Zhou HS, Liu DP, Liang CC. Challenges and strategies: The immune responses in gene therapy. Med Res Rev. 2004;24:748–761
  32. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245:1066–1072
  33. Rommens JM, Iannuzzi MC, Kerem BS. Identification of the cystic fibrosis gene: Chromosome walking and jumping. Science. 1989;245:1059–1065
  34. Hyde SC, Gill DR, Higgins CF, Trezise AE, MacVinish LJ, Cuthbert AW, et al. Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy. Nature. 1993;362:250–255
  35. Gray MA, Winpenny JP, Porteous DJ, Dorin JR, Argent BE. CFTR & calcium-activated chloride currents in pancreatic duct cells of a transgenic CF mouse. Am J Physiol. 1994;266:213–221
  36. Alton EW, Stern M, Farley R, et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet. 1999;353:947–954
  37. Kitson C, Angel B, Judd D, et al. The extra- and intracellular barriers to lipid and adenovirus-mediated pulmonary gene transfer in native sheep airway epithelium. Gene Ther. 1999;6:534–546
  38. Ferrari S, Geddes DM, Alton EW. Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis. Adv Drug Deliv Rev. 2002;54:1373–1393
  39. Halbert CL, Stanaert TA, Wilson CB, Miller AB. Successful re-administration of adeno-associated virus vectors to mouse lung requires transient immunosuppression during the initial exposure. J Virol. 1998;72:9795–9805
  40. Zabner J, Ramsey BW, Meeker DP, et al. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin Invest. 1996;97:1504–1511
  41. Dobson J. Magnetic nanoparticle-based gene delivery. Gene Ther. 2006;13:283–287
  42. Xenariou S, Griesenbach U, Ferrari S, et al. Using magnetic forces to enhance non-viral gene transfer to airway epithelium in vivo. Gene Ther. 2006;13:1445–1452

PII: S1526-0542(07)00005-X

doi: 10.1016/j.prrv.2007.02.005

Paediatric Respiratory Reviews
Volume 8, Issue 1 , Pages 62-66 , March 2007

Article Tools

* Image Usage & Resolution